Recruiting PHASE1 INTERVENTIONAL 4-arm NCT04900818

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

A Phase 1 Study of TJ033721 in Subjects With Advanced or Metastatic Solid Tumors

Sponsor: Bristol-Myers Squibb

Conditions Advanced Cancer Biliary Tract Cancer (BTC) Esophageal Adenocarcinoma Gastric Cancer Gastroesophageal Junction Carcinoma Metastatic Cancer PDAC - Pancreatic Ductal Adenocarcinoma Solid Tumor

Interventions TJ033721 (givastomig) TJ033721 (givastomig) , nivolumab, chemotherapy TJ033721 (givastomig), chemotherapy TJ033721 (givastomig), durvalumab, chemotherapy

Updated 15 times since 2021 Last updated: Mar 3, 2026 Started: Jun 29, 2021 Primary completion: Dec 31, 2026 Completion: Dec 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Advanced Cancer and Biliary Tract Cancer (BTC) and is currently actively recruiting participants. Bristol-Myers Squibb leads this study, which shows 15 recorded versions since 2021 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

15 versions recorded

Mar 2026 — Present [monthly]

Recruiting PHASE1
Sep 2025 — Mar 2026 [monthly]

Recruiting PHASE1
Feb 2025 — Sep 2025 [monthly]

Recruiting PHASE1
Sep 2024 — Feb 2025 [monthly]

Recruiting PHASE1
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE1

▶ Show 10 earlier versions

Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE1
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE1
Jul 2023 — Jun 2024 [monthly]

Recruiting PHASE1
Feb 2023 — Jul 2023 [monthly]

Recruiting PHASE1
Sep 2022 — Feb 2023 [monthly]

Recruiting PHASE1
May 2022 — Sep 2022 [monthly]

Recruiting PHASE1
Mar 2022 — May 2022 [monthly]

Recruiting PHASE1
Dec 2021 — Mar 2022 [monthly]

Recruiting PHASE1
Sep 2021 — Dec 2021 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Jun 2021 — Sep 2021 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bristol-Myers Squibb
I-Mab Biopharma US Limited

Data source: I-Mab Biopharma US Limited

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aurora, United States , Beijing, China , Boston, United States , Dallas, United States , Guangzhou, China , Hangzhou, China , Harbin, China , Hefei, China , Huntersville, United States , Layfayette, United States and 10 more locations